Myelostat Hydroxyurea Capsules

Hydroxyurea (Droxia, Hydrea, Hydroxycarbamide) treats cancer and severe sickle cell anaemia. In chemotherapy, Zydus Cadila Myelostat Hydroxyurea Capsules 500 mg are utilised.

Action Mechanism and Pharmacodynamics

Hydroxyurea inhibits ribonucleotide reductase, slowing DNA synthesis. This inhibitor also reduces cancer cell growth and sickle cell anaemia. Lowering cell formation with hydroxyurea reduces symptoms and prevents illness.

Indications and uses

1. Cancer Treatment: Hydroxyurea cures CML, squamous cell carcinomas, and certain ovarian cancers. It reduces tumours and treats cancer.
2. Sickle Cell anaemia: Treatment reduces hospitalisations and suffering. Red blood cell sickling is prevented by foetal haemoglobin production.
3. Others: Hydroxyurea reduces psoriasis and polycythemia vera red blood cell production.

Dosing & Administration

Give oral Myelostat Hydroxyurea capsules. Disease, weight, and treatment response determine drug dosage. Sickle cell anaemia may need 15–20 mg/kg/day, whereas cancer treatment may begin at 15. The patient’s blood counts and response dictate the dose.

Side Effects and Monitoring

• Side effects of bone marrow suppression include leukopenia, anaemia, and thrombocytopenia. Checking blood counts involves frequent testing.
• Frequent gastrointestinal concerns include nausea, vomiting, and anorexia.
• Hyperpigmentation, rash, and severe skin ulcers may ensue.
• Also, headache, dizziness, and elevated liver enzymes.

Hydroxyurea patients require periodic blood counts and renal and liver function tests to avoid severe side effects.

Clinical and Efficacy Studies

Clinical trials demonstrate Hydroxyurea improves chronic myelogenous leukaemia and sickle cell anaemia. Studies show sickle cell anaemia patients had lower white blood cell counts and fewer pain crises. Long-term use improves CML survival.

Patient Counselling and Education

Patients must comprehend drug monitoring and adherence. They should recognise side effects and report unusual symptoms immediately. Hydroxyurea is teratogenic. Thus, reproductive-age men and women should utilise contraception during and after treatment.

Conclusion

Myelostat Hydroxyurea Capsules cure cancer and sickle cell anaemia. This drug may improve patient outcomes and quality of life with proper administration, understanding, and monitoring. Hydroxyurea is used in oncological and haematological therapy because it benefits under controlled conditions despite potential side effects.